Sign in
4

Changes in Ownership

Seres Therapeutics, Inc. Filed Acc 0001209191-15-057217

CTO and EVP of Bioprocess Dev. acquired 34,090 shares (conversion)

From the SEC's structured data for this filing

Trades in this filing

Aunins John G. · CTO and EVP of Bioprocess Dev.

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2015-06-26 Conversion : show line 1 in the form +34,090 84,090 D

Table II: Derivative

2 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2015-06-26 Conversion : show line 2 in the form Series B Convertible Preferred Stock −34,090 34,090 0 D
2015-06-25 Grant or award : show line 3 in the form Stock Option (right to buy) +50,000 $18.00 2025-06-24 50,000 50,000 D
Loading xslF345X03/doc4.xml…